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Osteoblast Differentiation and Bone Matrix Formation
In Vivo and In Vitro
Harry C. Blair, MD,1,2 Quitterie C. Larrouture, MS,2 Yanan Li, MD, PhD,3 Hang Lin, PhD,4
Donna Beer-Stoltz, PhD,2 Li Liu, MD, PhD,2 Rocky S. Tuan, PhD,4 Lisa J. Robinson, MD,5,6
Paul H. Schlesinger, MD, PhD,7 and Deborah J. Nelson, PhD8
We review the characteristics of osteoblast differentiation and bone matrix synthesis. Bone in air breathing verte-
brates is a specialized tissue that developmentally replaces simpler solid tissues, usually cartilage. Bone is a living
organ bounded by a layer of osteoblasts that, because of transport and compartmentalization requirements, produce
bone matrix exclusively as an organized tight epithelium. With matrix growth, osteoblasts are reorganized and
incorporated into the matrix as living cells, osteocytes, which communicate with each other and surface epithelium
by cell processes within canaliculi in the matrix. The osteoblasts secrete the organic matrix, which are dense collagen
layers that alternate parallel and orthogonal to the axis of stress loading. Into this matrix is deposited extremely dense
hydroxyapatite-based mineral driven by both active and passive transport and pH control. As the matrix matures,
hydroxyapatite microcrystals are organized into a sophisticated composite in the collagen layer by nucleation in the
protein lattice. Recent studies on differentiating osteoblast precursors revealed a sophisticated proton export network
driving mineralization, a gene expression program organized with the compartmentalization of the osteoblast
epithelium that produces the mature bone matrix composite, despite varying serum calcium and phosphate. Key
issues not well defined include how new osteoblasts are incorporated in the epithelial layer, replacing those incor-
porated in the accumulating matrix. Development of bone in vitro is the subject of numerous projects using various
matrices and mesenchymal stem cell-derived preparations in bioreactors. These preparations reflect the structure of
bone to variable extents, and include cells at many different stages of differentiation. Major challenges are production
of bone matrix approaching the in vivo density and support for trabecular bone formation. In vitro differentiation is
limited by the organization and density of osteoblasts and by endogenous and exogenous inhibitors.
Keywords: tight junction, ClC chloride proton exchangers, NHE sodium-hydrogen exchangers, sodium hy-
drogen exchanger regulatory factor-1, BMP-2, sclerostin, bone morphogenetic proteins, activin/inhibin
Introduction
Bone, in the air-breathing vertebrates, is a highlyspecialized tissue with many advanced features not found
in bony fishes.1 During development, bone usually replaces
solid and avascular mesenchymal tissue, mainly mineralized
cartilage or fibrocartilage. These tissues are important, but
separate topics,2 which will not further be considered.
A key concept is that bone is a living organ with cellular
and structural components that have defined ontogeny and
biochemical functions. Particularly, the structural compo-
nent of living bone, the extracellular matrix, is separated
from general extracellular fluid by a tight epithelial layer
of osteoblasts. This principal is of highest importance,
and it is often not appreciated. It is exemplified in rapidly
fixed bone demonstrating its structure with minimal de-
generation (see Fig. 1). Osteoblasts in the organized epi-
thelioid structure secrete bone organic matrix, and remain
as a tight epithelium to control the matrix environment for
mineralization.
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2Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
3Department of Stomatology, Chinese PLA General Hospital, Beijing, China.
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With continuing growth, some osteoblasts are incorpo-
rated into the matrix as living cells, osteocytes, which are a
permanent part of the living organ. New osteoblasts are
recruited in a coordinated manner from mesenchymal stem
cells and committed osteoblast precursors to maintain the
continuous epithelial layer over actively forming bone.
These cells become osteocytes after incorporation into bone
matrix and communicate with each other and surface layer
osteoblasts through cell processes that run within canaliculi
that permeate the matrix.
FIG. 1. Characteristics of bone with special fixation and labeling protocols. (A) A low-power view from a preparation
previously published,1 showing the continuity of bone-lining osteoblasts (arrows) and well-preserved marrow; dark regions
are developing red blood cells. Briefly, this is a 1 mm section in epoxy, surface stained with methylene blue. For very-high-
quality fixation,2 mm fragments of freshly killed avian femoral trabecular bone immediately after sacrifice by CO2 inhalation,
were dropped into cold 2% glutaraldehyde and 1% paraformaldehyde. The animal was prepared with a low calcium diet to
soften the skeleton.45 (B) A low-power laser scanning confocal fluorescent photograph of the bone surface of rabbit femur
trabecular bone in an animal given tetracycline before sacrifice. Bone formation is labeled with tetracycline (green arrows);
other sites are unlabeled (white arrows). Thus, bone-lining cells are impermeable; during bone formation, basic calcium-
binding material, including calcein or tetracycline, is incorporated in hydroxyapatite. An unpublished image from the study.16
(C) A laser scanning confocal image from the study shown in (B), but in an animal treated for 4 weeks with high-dose
corticosteroids, inducing osteonecrosis.16 In the necrotic region, there is diffuse tetracycline uptake (green arrows), but not in
living bone (white arrows). Thus, when bone dies, it becomes permeable to low-MW substances, including hydroxyapatite-
binding molecules. Diffuse-nonspecific uptake is quantitatively much less than tetracycline transport during bone formation
(B); bright cells outside of the bone are marrow autofluorescence. (D) The basic features of osteoblast organization, an osteon.
Its structure is delineated by an impermeable cement line (left) and by surface osteoblasts connected by gap and tight junctions.
During bone mineral transport, the process of mineral deposition produces acid. Exclusively during mineral transport,
osteoblasts also transport hydroxyapatite-binding fluorescent molecules. (E) A high-power light photograph of a preparation
similar to (A), but fixed in the hypertonic medium. A tangential section of the bone surface reveals the dense tight junctions
between osteoblasts as spiky intercellular connections (arrows). (F) Bone is a highly vascular organ: a high-power light
photograph of active bone formation from the preparation shown in (A). Note the capillary (vessel) adjacent to the bone and the
continuous layer of osteoblasts adjacent to nonmineralized bone, osteoid, with osteocytes incorporated in the matrix.
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The organic matrix of bone is very dense, highly cross-
linked, type I collagen. It also contains quantitatively small
amounts of accessory proteins, including osteopontin and
osteocalcin, which are important in coordinating the organic
matrix and bone mineral.3 Collagen in mature bone is in
dense parallel layers that alternate in orientation, parallel to
and orthogonal to the axis of load, at *2mm intervals. Into
this collagen matrix is deposited hydroxyapatite-based mi-
crocrystals. Crystal nucleation is driven by two phases of
coupled transport, which removes protons and condenses the
mineral into the very dense hydroxyapatite microcrystals
required to form the strong and dense bone composite.
Adjacent to cells and cell processes, the matrix is not well
organized, reflecting the reorganization and condensation
guided by accessory proteins from initial nucleation, re-
sulting in dense lamellar structure of mature bone.4
Recent advances clarify the mechanism driving critical
initial mineralization. It requires two-phase removal of acid
evolved during hydroxyapatite nucleation by the osteoblast
epithelium enclosing the mineralization compartment. This
process allows mineral formation to proceed to completion
at varying serum calcium and phosphate.5 Once deposited,
the mineral undergoes maturation from amorphous calcium
phosphate to hydroxyapatite, with important changes in
mineral orientation and organization. This surprisingly slow
and complex process depends critically on pH.6
Poorly characterized processes include how new osteo-
blasts are incorporated into growing bone, a process that is,
at least in part, regulated by matrix vesicles,7 and the effects
of endogenous and cell-produced growth and differentiation
factors (GDFs) in vitro and in vivo. Key GDFs were estab-
lished long ago.8 The GDFs involved in bone development
also regulate other organs.8 What drives bone differentiation
is when and where GDFs occur in relation to the receptive
stage of the target cell. An important misconception is that
individual cytokines, including bone morphogenetic protein-
2 (BMP-2), are specific to bone.
Last, we will consider the development of bone in vitro.
This is the subject of numerous projects that use either tissue
culture plates or a variety of matrices and mesenchymal stem
cell-derived preparations in bioreactors. These preparations
reflect the structure of bone to variable extents and include
cells at many different stages of differentiation. Difficulties
include production of trabecular bone and quantitative pro-
duction of bone matrix approaching its natural density. Mis-
conceptions associated with tissue culture bone include ‘‘2D
cultures’’ making bone; bone developing on tissue culture
plates occurs where dense, typically nodular, aggregates of
osteoblasts can secrete matrix (vide infra). Cultures without
artificial scaffolds are called 2D, but really are not. Challenges
include that bone production in vitro is self-limited. The
reasons are complex; among these, sclerostin is produced in
large concentrations by osteoblast cultures9 and glucocorti-
coids inhibit osteoblast proliferation.10 This and related issues
may be addressed by better and more detailed tissue engi-
neering approaches.
Fundamental Bone Organization and Cell Biology
Osteoblasts, when forming bone, are cuboidal cells with large
amounts of rough endoplasmic reticulum and mitochondria.11 In
older work using osteoblasts in cell culture media, the high
oxidative activity of osteoblasts was identified. However, in vivo,
fatty acids are a key source for bone synthesis12; elimination of
the major HDL component causes severe osteoporosis.13 Os-
teoblasts that are not synthesizing bone are low-columnar cells,
but still form a continuous membrane (Fig. 1A).
Table 1 shows important osteoblast RNA expression by
functional class. To allow comparison of data by relative ex-
pression, we show hybridization levels and p-values from two
of our human osteoblast cRNA gene screens, with references to
literature reports that reported similar expression of each target
in other cell preparations. Since many workers have performed
studies of this type, data in many references overlap and we
regret that it is not possible to reference all studies.
The synthetic bone matrix side of the osteoblast is its apical
surface. The apical surface is, among other things, the site of
massive membrane-bound alkaline phosphatase.37 Bone al-
kaline phosphatase is a good indicator of bone synthesis.38
Alkaline phosphatase is necessary to supply phosphate for
bone mineral, but it alone is not sufficient for mineralization,
further discussed below. At the apical surface, osteoblasts
secrete large amounts of type I collagen and smaller amounts
of matrix organizing proteins, including osteocalcin and os-
teopontin.39 Osteocalcin is transcribed, for practical purposes,
only for the organic matrix; so it is a useful indicator of os-
teoblast synthetic activity; it is also a signaling molecule.19
The organic bone matrix is a hydrated protein matrix, called
osteoid. The side of the osteoblast oriented toward the bone
marrow or the periosteum is its basolateral surface.
Bone formation begins at a cement line, a thin layer of
mineral through which no cell processes pass, generally laid
down at a site cleared by osteoclasts and then immediately
occupied by an epithelioid layer of osteoblasts. Little is
known about the composition of the cement line, although it
may have a different protein–mineral mixture than in bone.40
Gap junction-connected groups of osteoblasts making bone,
at a cement line, and extending several layers of cells to the
bone surface is called an osteon. All cells in an osteon are
connected by gap junctions centered on connexin 43.41 Pro-
cesses of osteoblasts and osteocytes overlap in the canaliculi,
so the surface area of the cellular connections is much larger
than suggested by the narrowness of the canaliculi.
The osteocytes, osteoblasts buried in bone matrix, live as
long as the bone lives and are an essential feature of bone.
Osteocytes retain connections with the surface layer of os-
teoblasts.42,43 In devitalized bone, the canaliculi formerly
occupied by processes of osteocytes and osteoblasts can be
filled with dye, classically India ink, to visualize the system,
which is still useful in teaching.
Bone is a living organ maintained by living cells, osteo-
blasts and osteoclasts. The alkaline nature of bone forma-
tion, with the defining ectoenzyme alkaline phosphatase
and, in contrast, the acidic environment of bone degradation
by osteoclasts, containing acid phosphatase, were appreci-
ated 60 years ago.44 Maintaining these pH gradients in jux-
taposed compartments requires physical isolation (Fig. 1A)
and directed transport between high or low pH compartments
and the extracellular fluid.
More specifically, pH gradients require tight control of ac-
cess to the bone surface, including a barrier to diffusion. This is
demonstrable in vivo using low-molecular-weight (MW) hy-
droxyapatite-binding fluorescent ions, including the fluores-
cent compounds tetracycline, calcein, and congeners. These are
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strictly excluded from bone, with two important exceptions:
during bone formation, when large amounts of calcium and
phosphate are transported across secretory osteoblasts, calcium
binding fluorescent molecules are cotransported (Fig. 1B). This
was discovered by Harold M. Frost in the late 1950s. In addition
to showing that bone in general is impermeable, this discovery
provided a tool for measuring bone formation.46 The calcium
binding fluorescent dyes or phosphate analogs, including bi-
sphosphonates, are bound to, and included in, the mineral
matrix during mineral accumulation, as demonstrated by far red
fluorescent bisphosphonates.47
The second exception is that dead bone is nonspecifically
permeable.16 In the example of regional osteonecrosis, bone
becomes immediately and nonspecifically permeable to tetra-
cycline. In dead bone, there is free diffusion through the matrix
and diffuse dye binding (Fig. 1C). In contrast, during mineral
Table 1. Expression of Selected mRNAs in Human Osteoblast Cultures:
Data Using Affymetrix cRNA Hybridization as Described
14
Gene Description Hybridization p Consistent reports
Conversion of cartilage to bone and regulators of osteoclast formation. In osteoblasts, VEGF, RANKL, and osteoprotegerin
all are upregulated by adrenocorticotropic hormone (ACTH).15 In high-dose glucocorticoid treatment, ACTH is
suppressed and osteonecrosis may occur (see Fig. 1B, C).16
VEGF Vascular endothelial growth factor-1 830 0.0007
TNFRSF11B Osteoprotegerin 770 0.0002
TNFSF11 Receptor activator of nuclear factor-kB 190 0.01 15,17,18
Bone structural proteins. Osteoblasts make more type 1 collagen than any other cell, by a wide margin. Alkaline
phosphatase is an ectoenzyme, highly expressed in active osteoblasts at the apical membrane. Osteocalcin occurs only in
bone and may also function in signaling.19
COL1A1 Type 1 collagen, a-1 chain 21,300 0.0002
ALPL Alkaline phosphatase 2800 0.0002
BGLAP Osteocalcin 1200 0.0002 9,18,20
Secretory osteoblast transport and regulation proteins. Sodium–hydrogen exchangers 1 and 6 are expressed in basolateral
surface active osteoblasts21; the sodium–hydrogen exchanger regulatory factor-1 is confined to the basolateral
surface active osteoblasts and regulates osteoblast differentiation.22,23 Chloride proton exchangers CLC3 and CLC5 are
highly expressed in apical surfaces of active osteoblasts; CLC5 is quantitatively suppressed when CLC3 is present.5
SLC9A6 Sodium–hydrogen exchanger-6 1300 0.0002
SLC9A3R1 Na/H exchanger regulatory factor-1 540 0.01
CLCN3 Chloride proton antiport-3 2000 0.0002
CLCN5 Chloride proton antiport-5 300 0.0002 5,21–23
Characteristic of osteocytes. Sclerostin inhibits bone formation by binding LRP5/6 and may be a factor limiting the
success of bioreactor results.24,25
SOST Sclerostin 3000 0.0002 9
Bone morphogenetic protein superfamily. Comment: Expressed on cell surfaces; induce differentiation. Transforming
growth factors, BMPs, and activin/inhibin are all dimers. TGFb is not specific for cartilage; it is widely expressed.26 Type
1 and type 2 receptors are required for signaling. Many BMPs signal through the same receptors; none are bone specific,
including BMP-2.27–30 Endogenous BMP expression is a major reason added BMPs are often ineffective in tissue
cultures.
TGFB1 Transforming growth factor b1 6500 0.0002
BMP-1 Bone morphogenetic protein-1 3800 0.0002
BMP-2 Bone morphogenetic protein-2 600 0.01
BMP-10 Bone morphogenetic protein-10 180 0.05
INHBA Inhibin bA, component of activin and inhibin 2100 0.0002
INHA Inhibin a chain 200 0.02
INHBC Inhibin b C chain 430 0.0002
TGFBR1 Transforming growth factor b receptor-1 610 0.01
TGFBR2 Transforming growth factor b receptor-2 740 0.0007
BMPR1A BMP receptor type 1 isoform A 1600 0.0002
BMPR2 BMP receptor type 2 460 0.01
ACVR1 Type 1 activin receptor, related to BMPR1 5100 0.0002
ACVR2 Type 2 activin receptor, related to BMPR2 710 0.01 18,31–36
Hybridization averages analysis of two human osteoblast cultures at 2 weeks in a bone differentiation medium. Background is *100 U.
n = 18, rounded to two significant places; exact p-values. The last column cites studies reporting consistent data, mainly for human cells in
an osteoblast medium, in a few cases for mouse mesenchymal stem cells (MSC).
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transport, hydroxyapatite binding dyes are vectorially trans-
ported at high concentrations in new mineral (Fig. 1B).
Figure 1B and C are unpublished frames from our study.16 An
osteon with tight and gap junctions representing the active
process of bone synthesis is diagrammed in Figure 1D.
Active Transport Supports Rapid and Quantitative
Vectorial Mineralization
The mechanism by which the mineralization is driven
rapidly to completion is only now becoming clear. The key
to understanding this is centered on equation of mineral
formation:
6HPO4
2þ 2H2Oþ 10 Ca2þ4 Ca10 PO4ð Þ6 OHð Þ2þ 8Hþ
Equation 1
This simple equation ignores intermediates, calcium phos-
phates, which later mature into hydroxyapatite. Furthermore,
many substitutions occur in intermediates, including carbon-
ates. Nevertheless, the equation is key to understanding the
thermodynamics of bone formation, including how very dense
mineral can be accumulated, in a vectorial manner, at a constant
rapid rate under a wide variety of serum mineral and pH con-
ditions. To drive bone mineralization the export of acid from
the forming matrix is critical. This requires isolation of the
matrix from general extracellular fluid, as we have observed
and discussed elsewhere (above - ‘‘Exclusion of Low-MW
Ions’’, and following - ‘‘Exceptions That Require Additional
Transporters.’’ Other aspects of mineralization, including im-
portant accessory proteins that support crystal nucleation,
which is important for ultimate bone strength,3 are discussed
below in Matrix Maturation and pH section.
Chemists interested in hydroxyapatite deposition have long
been aware that this requires removal of protons for mineral
precipitation,48 just as addition of protons is essential for re-
covery of ionic phosphate and calcium during bone resorp-
tion.49 It was difficult to explore transport mechanisms in the
pregenomic world, but studies in the 1980 s using pH mea-
surements, while manipulating extracellular ions, showed
high-capacity sodium-hydrogen exchange, removing acid
from osteoblasts.50,51
A classic view was that tissues mineralize in open systems;
this is indeed the case in dystrophic calcification or calcium
phosphate crystals in vitro, including in bone cell cultures; this
is not bone, and distinguishing dye binding of calcium salts
from bone is an important problem.52 In cartilage, which has no
boundary epithelium, acid can diffuse away and mineral can
form solely supported by alkaline phosphatase; in the alkaline
phosphatase knockout, mineralized cartilage is absent.53
In a closed space, such as the isolated matrix lined by
impervious osteoblasts, removing the acid will drive mineral
formation strongly to completion, very rapid formation of
extremely dense mineral possible. This is what happens in
true bone. Figure 2A shows our model of the canonical
mineralization process. The model centers on H+ removal to
drive mineral precipitation to completion (Equation 1); since
bone is a tight epithelium, there are also passive calcium
transporters and neutral phosphate transporter-1 (NPT1) that
supply the ions for mineral deposition.23,54
Transporters in the epithelioid osteoblasts mediate acid
uptake from bone matrix at the osteoblast apical membranes
and acid extrusion at the basolateral membranes. On their
basolateral membranes, osteoblasts express sodium-hydrogen
exchangers 1 and 6 (Fig. 2B).21 On the apical membranes,
Cl2/H+ exchangers move acid into osteoblasts (Fig. 2C).5 This
process and osteoblast phosphate transport are regulated by
the sodium–hydrogen exchanger regulatory factor-1.22
It is established that osteoblast apical membrane phospha-
tases, particularly alkaline phosphatase, also to some extent
PHOSPHO1, and in a complex and sometimes inhibitory
manner ENPP1,55,56 regulate phosphate production that is es-
sential for mineralization. On the other hand, when ClC3 and 5
are absent, there is normal alkaline phosphatase activity, but no
mineral production (Fig. 2D).5 The phosphate supply is nor-
mal, but the osteoblasts cannot make the gradient that drives
mineral transport to completion (Equation 1). Important pro-
cesses are not accounted by this model: Osteoid is a dense
collagen hydrogel; when osteoid is mineralized, the water is
eliminated. Clearly, water transport vectorially out of new
bone is necessary; tissue arrays suggest that osteoblasts
express aquaporins.57 Ion transporters that balance the ClC
and NHE exchangers are also not known, although direct
measurement in osteosarcoma cells revealed outwardly rec-
tifying K+ channels, which might drive ClC exchangers.58
Other ion transporters are required, and remain to be studied,
at the basolateral surface, an outward pump of net sodium,
and at the apical surface, reuptake of chloride.
Exclusion of Low-MW Ions, and Exceptions
That Require Additional Transporters
To exclude low-MW charged molecules from the bone
matrix, tight junctions between cells are required. These are
demonstrated in osteoblasts fixed in a hypotonic medium
(Fig. 1E). Numerous studies have consistently reported these
at cellular, ultrastructural, and biochemical levels.59–63
This implies that the local uptake of calcium binding ions
and fluorescent probes during bone synthesis (Fig. 1B, C)
cannot be by diffusion. The bone mineral components, phos-
phate and calcium, are transported by specific membrane
channels such as the NPT2,23 which do not cotransport hy-
droxyapatite binding molecules. These would not be trans-
ported as hydroxyapatite complexes, but rather bind to
hydroxyapatite with high affinity after their transport. In this
regard, osteoblasts strongly express SLC21 and SLC22 anion
and cation transporters,64 and ABCC1 multidrug exporters.65
Our whole-exome cRNA screens in nontransformed human
osteoblasts (not illustrated) showed high expression of SLC21/
22 and ABCC1 as reported in transformed osteoblasts.64,65 No
direct experimental evidence of dye transporters is reported.
Coordination of Bone Development and Maturation
Bone is highly vascular with a network of capillaries adjacent
to active bone formation (Fig. 1F). This is important to support
the demands of bone synthesis for collagen production and
mineral transport, and is subject osteonecrosis during stress that
reduces its vascular supply. The peritrabecular capillaries are
delicate and usually lost in routinely fixed tissue. There are in-
teresting endocrinological support issues; synthetic osteoblasts
make large amounts of vascular endothelial growth factor
(VEGF) (Table 1), which is, in large part, supported by adre-
nocorticotropic hormone. When adrenocorticotropic homone
(ACTH) is suppressed by large quantities of glucocorticoids, this
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causes osteonecrosis affecting regions of the skeleton that have
active remodeling, such as the femoral head.15,16
Matrix vesicles
Bone synthesis is characterized by massive numbers of
membrane vesicles shed at the apical surface of synthetic
osteoblasts (not illustrated). These vesicles may have a
number of functions, including cellular communication66
and in extending cell membrane surface to support miner-
alization.67 A widely held view is that matrix vesicles are
important in hydroxyapatite crystal nucleation.68 While
important features of bone, these vesicles are not the single
force that drives dense mineral accumulation to completion.
They provide no means for the elimination of acid extracted
from the maturing mineral (Equation 1 and Fig. 2).
Matrix maturation and pH
Although the overall process of transport for dense min-
eral accumulation can be put simply (Equation 1), the pro-
cess also includes intermediate steps and is coordinated with
accessory proteins and collagen in a maturation process,3,4
where fully mature matrix may not be complete for days.
This process involves maturation of calcium phosphates at
nucleation sites into stable hydroxyapatite crystals and
FIG. 2. Major mechanisms of osteoblast acid transport that support complete conversion of phosphate and calcium to
hydroxyapatite. Osteoblasts actively transport phosphate,23 which is converted from pyrophosphate or nucleotide phos-
phates by alkaline phosphatase and other phosphatases. Hydroxyapatite is organized, in part, by accessory proteins, but the
process of crystallization generates massive amounts of acid. Removal of this acid has the effect of driving precipitation to
completion, regardless of extracellular conditions. (A) Key mechanisms driving bone mineral formation to completion
include uptake of acid by ClC exchangers at the apical membrane, and acid transcytosis with elimination by NHE
exchangers at the basolateral membrane. Modified from,5 with permission. (B) Demonstration of massive sodium–hydrogen
exchange capacity. Osteoblasts exposed to a large acid load, 30 mM propionic acid, a membrane-permeant organic acid,
maintain their internal pH at neutral in the presence of sodium. In the absence of sodium, the cells acidify dramatically. The
acid resistance is due to two highly expressed sodium–hydrogen exchangers on the basolateral membranes of osteoblasts.
Modified from Liu et al.,21 with permission. (C) Human osteoblasts express the chloride-hydrogen exchanger ClC3 at high
levels. Fluorescent antibody labeling of ClC3 in bone cortex is shown; the osteoblastic surface is at top and there is very
high expression of ClC3 in the apical membranes. The diagram at right shows cells and processes, the labeling of which is
demonstrated in the photograph. ClC3 occurs also in the canalicular system. ClC3-knockout controls were unlabeled (not
shown). If ClC3 is knocked out, ClC5 expression increases and has the same pattern of expression (not shown). Modified
from Larrouture et al.,5 with permission. (D) Bone formation by wild-type and ClC3/5-null osteoblasts. Wild-type murine
osteoblasts make bone in characteristic nodules with very strong mineral deposition or alkaline phosphatase activity (left
panels). Osteoblasts express two ClCs, 3 and 5, on their apical membranes. When ClC3 is knocked out, there is a minor
bone phenotype (not shown).5 When both ClC3 and 5 are eliminated, there is no mineralization (top right). The lack of ClC
expression does not affect alkaline phosphatase expression (bottom). Two centimeter diameter cultures, in six-well plates, of
murine osteoblasts at 14 days in the osteoblast medium without cortisol. Modified from Larrouture et al.,5 with permission.
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association of hydroxyapatite crystals with binding sites on
collagen. Physical chemistry provides a useful further view
of this: the presence of repeating charge alignment on
collagen suggested that a nucleation lattice might be
present.69–71 However, it has not been possible experi-
mentally to demonstrate nucleation sites on the nanometer
scale. Recent simulation studies suggested that a three-
dimensional (3D) nucleation site could be identified.72 A
particularly interesting aspect of mineralization of in-
trafibrillar collagen is that it only occurs experimentally
when the pH is held at mildly alkaline levels.73 This is
consistent with disruption of osteoclast inward acidifica-
tion of the bone surface disrupting solubilization of bone
mineral,74 and disruption of osteoblast outward proton
transport preventing dense mineral deposition (Fig. 2).5
Key Cytokines, GDFs, for Osteoblast Differentiation
It is impractical to review all the signals that affect os-
teoblast formation and activity; key classes are presented.
Some key GDFs for bone are included in Table 1.
Systemic hormones
Many systemic hormones function in bone, including pitui-
tary hormones, including ACTH, follicle stimulating hormone,
and thyroid stimulating hormone,14,15,75 once thought to
function only by steroid production in endocrine organs. The
steroid hormone family, particularly cortisol,76 sex steroids,77
and thyroxin (not a steroid, but signaling in the same man-
ner)78 are important. Cortisol does not stimulate bone matrix
synthesis, but it can stimulate osteoblast differentiation, dis-
cussed below. Both parathyroid hormone (PTH) and PTHrp are
important signals regulating osteoblasts,79 including regulation
of proteins that coordinate bone formation and resorption
(Table 1). The PTH receptor 1 is a G-protein-coupled receptor,
one of several, including the calcium-sensing receptor and Wnt
receptors that regulate osteoblasts.79
Fundamental regulators of bone development
VEGF and angiogenic hormone receptors are required for
bone formation.80,81 VEGF is required for conversion of
cartilage to bone and remains important in maintaining bone
viability during bone synthesis.15,81
Three classes of (usually) cell surface- or matrix-bound
GDFs have profound effects on osteoblast differentiation,
the transforming growth factor b (TGFb) superfamily (in-
cluding BMPs and GDFs), the FGF family, and the TNF
family. Additional regulators of differentiation important in
sites of bone growth and regulation of bone mass include
Indian hedgehog, Wnts, and sclerostin.82,83
The TGFb superfamily has many proteins that signal
through a few receptors (Table 1). Its many promoters
contain a large part of the information driving skeletal
modeling and are important in repair and regeneration.84 A
dramatic example is the focal expression of GDF5 (a BMP)
at sites where digits separate in the embryo.85 Signals of the
TGFb superfamily, which includes BMPs, activin, GDFs,
and TGFb, are required for bone formation, including the
cartilage formation that usually precedes bone formation.
BMP-2 or one of its cosignaling BMPs is a requirement for
bone formation. A common misconception is that a specific
BMP is selective for osteoblast differentiation. Particularly,
BMP-2 is not specific for osteoblast differentiation; its
presence alone will not produce bone. BMP-2 is involved in
pancreas/liver fate assignment in organogenesis.27 In epi-
dermal regeneration, BMP-2 is an essential signal,28 and
BMP-2 regulates a variety of other events in organogene-
sis.29 Furthermore, adding BMP-2 to osteoblast cultures
usually has little effect, reflecting that differentiating MSCs
intrinsically make large quantities of cell membrane-bound
BMPs, including BMP-2 (Table 1). Activin and BMP re-
ceptors can substitute for one another.29,30 BMP receptors
are of two types, with type 1 and type 2 receptors binding to
a dimeric BMP. The type 2 activin and BMP receptors,
which have serine/threonine kinase activity, are regulated by
formation of the complexes. While different BMPs are ex-
pressed at specific times and places for differentiation,
several of them can produce the same effect by the same
receptors. What is essential is that signals and receptors occur
at the proper time and place, with signaling generally highly
localized,85 with BMPs in vivo being membrane tethered.
Indeed, scavenger receptors eliminate BMPs that might es-
cape their presenting cell, such as noggin, absence of which
prevents normal separation of individual bones.86,87
FGF family signals, again with redundant cytokines sig-
naling by fewer receptors, regulate bone formation, partic-
ularly being important in cartilaginous precursors,88 at sites
adjacent to epithelium, and remain active in osteoblast dif-
ferentiation.89 FGFs are usually heparin bound; two or more
molecules are required to activate dimeric receptors.90
FGF23 is a specialized signal produced by osteocytes that
downregulates phosphate reabsorption in the kidney.91
TNF family signals prominently include RANKL pro-
duced by osteoblasts, which regulate osteoclast differentia-
tion, and osteoprotegerin, a decoy receptor that binds
RANKL, which limits RANKL signaling (Table 1), these
regulated by PTH and other signals.92 Many additional
TNFs and receptors are present on osteoblasts and have
specialized regulatory functions.93,94
Bone Formation In Vitro
Two dimensional and 3D cultures
Mesenchymal stem cells or committed osteoblast cultures
are usually called ‘‘2D’’ when cells are plated without an
artificial matrix support, which, if used, is typically a hydro-
gel, and in which case, the cultures are termed ‘‘3D.’’ These
terms are, at least in part, misleading. There is no such thing as
2D bone; individual osteoblasts cannot make bone and when
bone forms in osteons, it always has depth. Dense bone
formed in vitro in tissue culture plates without artificial matrix
occurs usually in nodular form, as we showed in the cell
cultures used for demonstration of sodium-hydrogen ex-
change in human osteoblasts.21 Similar examples are shown
in Figure 3A and B, with von Kossa stain or alkaline phos-
phatase activity demonstrated. Alkaline phosphatase activity
is extremely high in areas of extracellular matrix minerali-
zation, and generally appears nearly black by a-naphthol
phosphate/Fast Blue RR labeling of phosphatase activity.
That this really is bone, that is, dense extracellular collagen
into which mineral is transported, can be substantiated in a
number of ways, a straightforward being to embed and section
the bone. The extracellular collagen matrix can then be
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demonstrated directly by its birefringence (Fig. 3C, D), ex-
actly as it is used for thin sections ex vivo to demonstrate
woven or lamellar bone.95 A disadvantage of polarized light
birefringence is that it will not work on most types of plastic;
glass slides, used here, are needed. It may also be useful to
demonstrate the type I collagen directly, although this is
rarely done.
Permissive conditions; inclusion of glucocorticoids
often is counter-productive
Bone differentiation is fostered in vitro from mesenchymal
stem cells using permissive conditions, including ascorbic acid
and a phosphatase substrate, usually glycerol-2-phosphate (b-
glycerol phosphate).96 Natural substrates, pyrophosphate and
nucleotide phosphates,97 tend not to work well in vitro; par-
ticularly, pyrophosphate is an inhibitor when added to the ex-
tracellular space, despite that, osteoblasts secrete it into the
phosphatase-rich mineral formation space. High concentra-
tions of ATP can inhibit mineralization; in its natural role, it is
rapidly degraded and ATP does not accumulate; adenosine
itself promotes osteoblast differentiation.98 From the 1990s,
glucocorticoids have often been included.96 Glucocorticoids
promote osteoblast survival76 and permit differentiation,96 but
they greatly reduce proliferation.10 Thus, glucocorticoids
might speed alkaline phosphatase expression, but bone matrix
FIG. 3. Characteristics of osteoblast cultures with and without hydrogel support. (A) In high-quality osteoblast cultures in a
permissive medium without supporting gels, expanding dome-like mineralized bone matrix is produced. This is an unpublished
photograph of a preparation made as reported.21 Matrix produced by human osteoblasts 3 weeks in a medium with glycerol-2-
phosphate and ascorbic acid. The matrix is silver stained (von Kossa) and shows regions of dense extracellular matrix with
lucencies corresponding to cells incorporated in matrix (arrows). The culture is shown in phase to emphasize the dense
osteoblast layer surrounding the bone. A low-power field, 0.8 mm across. (B) Alkaline phosphatase activity in a duplicate well
of the same preparation as (A).21 Where extracellular mineralized matrix occurs (matrix), alkaline phosphatase in surface cells
is strongly active and appears black by a-naphthol phosphate—fast blue RR staining. In nonmineralizing areas, cells expressing
alkaline phosphatase are outlined by blue; the enzyme is membrane bound. This culture is also shown in phase, and the line of
osteoblast surrounding the bone nodule is clearly seen (arrows). (C) A culture similar to (B) embedded in epon (epoxy) and cut
as a 1mm section, stained with methylene blue to demonstrate the extracellular matrix containing osteocytes. Dense osteoblasts
line the left side of the section. (D) The same section as (C) photographed with crossed polarizers to demonstrate collagen fibrils
by their birefringence, which is blue-green or red depending on the orientation. The orientation of fibrils, as in living bone, is in
layers oriented at right angles. (E) A culture of human osteoblasts on tissue culture plastic where one cell (arrow) was injected
with lucifer yellow, a low-molecular-weight fluor that is small enough to pass through gap junctions. Note that cell processes
and adjacent cells are labeled. From published work,93 used with permission. (F) A culture of human mesenchymal stem cells in
the osteoblast differentiation medium in 1.5% hydrogel polyethylene glycol diacrylate photo-crosslinked. The culture is stained
with calcein acetoxymethyl ester (nuclei bright green, cytoplasm green) and propidium iodide (dead nuclei red). Intercellular
connections are seen. A few are indicated by arrows; note similarity to processes in (D); over 80% of the cells are alive 12 days
after encapsulation. In addition to intercellular connections, groups of closely apposed cells occur (arrowheads). (G) Murine
MSCs encapsulated in 10% gelatin hydrogel in the bone differentiation medium for 7 days. Shrunken dead cells that have
accumulated calcium (dystrophic calcification) by alizarin red staining; there is no extracellular matrix (see Fig. 3D). The
gelatin capsule around one cell is indicated (arrows). This is intracelluar calcium, extracellular calcium phosphate crystals also
stain and are not bone.52 (H) A von Kossa stain of MSC from ClC3-knockout animals in the bone differentiation medium,
without hydrogel supports, 21 days. An unpublished photograph from the published study.5 Note the trabecular pattern of the
mineralized matrix, which contains dense collagen (not illustrated). MSC, mesenchymal stem cells.
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formation is suppressed, often severely, because cell division is
needed to enlarge bone-forming units.
Furthermore, solutions with *10 mM glycerol-2-phosphate
and 1.5 mM calcium, with high alkaline phosphatase activity,
and buffered to pH 7.4, over time, accumulate crystals of
acellular and organic matrix-free calcium phosphates.52 Neither
von Kossa nor alizarin red binding to crystals indicate bone.
Bone is delimited by cells and requires that mineral is deposited
in the dense collagen matrix. Bone forms only in dense cell
cultures, and it is important not to mistake staining with alizarin
red or silver of dead cells (dystrophic calcification) for bone.
The bone nodules shown in Figure 3A–D were produced
without glucocorticoids; we find that with either murine or
human osteoblasts, more consistent bone is formed without
glucocorticoids. Murine cells are resistant to glucocorticoids;
so reduction of bone synthesis in this case tends to be less.
Earlier, highly successful bovine in vitro bone differentiation
did not use glucocorticoids.99 It became fashionable in the
1990 s to add glucocorticoids to study osteoblast marker ex-
pression,96 but glucocorticoids do not improve bone matrix
production.10
Osteoblast differentiation requires GDFs
These are largely produced by the cultures themselves (Ta-
ble 1), but the order of differentiation and intermediate stages are
not known. So one waits for spontaneous bone formation. Even
in the rare progressive disease, fibrodysplasia ossificans pro-
gressiva,30 where the body slowly is encased in ectopic bone
with an activating mutation in ACVR1 (Table 1), ectopic bone
formation occurs when minor trauma disturbs the metastable
condition of mesenchymal stem cells that bear the constitutively
active BMP receptor. What factors the minor trauma induces,
probably quite locally, are not known at this point.
Bone is a tissue, composed of multiple cell types
Cells at many different stages of development occur in mes-
enchymal stem cell cultures. In consequence many more cyto-
kines occur, than is expected. This includes high amounts of
TGFb (Table 1), and in keeping with this cartilage-associated
agent, the cultures make aggrecan (not shown; it is the protein
core of a key proteoglycan). Demonstration of cartilage in vitro,
generally fibrocartilage, requires pellet cultures, but may be
accomplished on membranes with special atmosphere.100 This is
relevant because when bone nodules form, they may do so ad-
jacent to cells with, at least, partial cartilage characteristics,101 as
occurs in vivo in callus. Careful examination of cultures with
nodular bone also often discloses tubular structures with capil-
lary antigen markers.15 This is expected; mesenchymal stem
cells undergo vascular differentiation with VEGF.102
Critical Evaluation of Suitable Conditions
for Bone Formation In Vitro
Murine cells usually differentiate to form bone in about 14–
21 days. Human cells take longer to produce mineralized matrix,
often 28 days. Unconstrained osteoblasts differentiating in vitro
have many intercellular connections, including abundant con-
nexin 43 gap junctions.93 In consequence, injection of the low-
MW fluor lucifer yellow into one osteoblast labels the cell, cell
processes, and many adjacent cells (Fig. 3E). This is important in
making 3D cultures that require hydrogels to prevent cells set-
tling out of the culture. A practical method to determine if a
hydrogel is porous enough to allow cell processes to permeate
the gel is to label it with calcein acetoxymethyl ester, which
allows the cell–cell communication to be seen (Fig. 3F). If cells
are constrained from making cell–cell contacts, they make no
bone and also die (Fig. 3G). The cells undergo anoikis, a form of
apoptosis affecting anchorage-dependent cells. This culture
(Fig. 3G) is also an example of alizarin red staining that is not
bone: the dead cells have undergone dystrophic calcification,
which should not be mistaken for extracellular matrix. In addi-
tion to cell–cell attachments, proteins that allow integrin binding
to cells, including intact collagen, may suppress apoptosis.103
Fine granular precipitates of calcium phosphates, not bound by
or including cells, are not bone.52
Improving Bone Quality In Vitro
Frequently, especially in hydrogel-supported cultures,
PCR is required to detect increases in bone markers; in-
creases relative to MSC precursors may be less than 10-fold.
In the best dense unsupported osteoblast differentiation, key
osteoblast proteins increase *200–300-fold.22
Improving quantitative bone differentiation may involve
providing surfaces to nucleate osteon formation, increased
cell density, management of nutrient flow, and other factors.
The normal osteon forms where existing extracellular matrix,
cartilage, or bone is eroded by osteoclasts. A cement line is
secreted at this site (Fig. 1D). The site contains residual
material secreted by osteoclasts, including tartrate-resistant
acid phosphatase. There is direct evidence that tartrate re-
sistant acid phosphatase is osteoinductive,104 but the utility of
making conditioned artificial calcified templates for osteo-
blast attachment has not been investigated fully. Many re-
sorbable substrates have been tested, often with added growth
factors.105 Other advances include our discovery that ClC3-
knockout cells make trabecular bone in vitro (Fig. 3H).5 If this
mouse phenotype translates into human cells and can be
scaled, it has potential. Important considerations in further
work include accounting for growth factor production by
implanted cells (Table 1), and the natural expression of
growth factors generally is as membrane-tethered proteins on
presenting cells adjacent to the responding cells. Calcium
phosphate ceramics as bone-inducing agents show results
often comparable to bone grafts.106,107 In bioreactors, results
often lag, often reflecting limitations in cell density.
Cultures of MSCs that form bone nodules can induce
capillary formation.15 The degree of feedback on osteo-
blasts from vascular cells around bone is unknown. Related
considerations are hypoxia-induced factors (HIF). HIF1a is
highly expressed in osteoblasts in vitro even at high oxygen
tension. Many studies have shown that HIF1a negatively
effects bone matrix production, while fostering cell sur-
vival.108–110 The pathway is complex, and feeds back in
production of VEGF and BMP production.111,112
In cell cultures, many osteoblast precursors form osteocyte-
like connections (Fig. 3E); how this affects further cell dif-
ferentiation is uncertain, but there definitely is high produc-
tion of sclerostin in human osteoblast cultures (Table 1), and
sclerostin inhibits mineralized bone formation.113,114 Potential
methods for limiting effects in vitro include blocking anti-
bodies,114 or knockdown of sclerostin in mesenchymal stem
cells used for bone differentiation.
276 BLAIR ET AL.
Conclusion
New understanding of bone physiology, including the role
of ion transporters in bone formation, will make it possible
to refine models for control of bone formation, in vivo and
in vitro. Management of bone in vivo will increasingly ac-
count for factors including ACTH support of bone vascu-
lature. It is likely that complete success of mesenchymal
stem cell differentiation in vitro for bone transplant will
require osteoblast binding and differentiation sites, in part,
reflecting the transport processes that push mineralization of
dense bone matrix in living bone (Fig. 2C). Sophisticated
models that account for production of inhibitory cytokines,
such as sclerostin, are needed. Production of trabecular bone
in vitro may be important. Trabecular bone has a high sur-
face to volume ratio that may facilitate revascularization and
remodeling.
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Louis-Plence, P., Apparailly, F., Canovas, F., Rème, T.,
Sany, J., Jorgensen, C., and Noël, D. Transcriptional
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